Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11842706 | 0.77 | CA12 (0.39) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL29122407 | 0.77 | CA12 (0.46) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL3991346 | 0.77 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL8916507 | 0.77 | CA12 (0.42) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL5742303 | 0.77 | CA12 (0.46) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL14645780 | 0.77 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL5239461 | 0.77 | CA12 (0.39) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL22091994 | 0.77 | CA12 (0.46) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL21805912 | 0.77 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| Hydrochloric Acid SCHEMBL29178589 | 0.75 | CA12 (0.55) | CA12CA1CA9CA2PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | CA12 4716/4885CA1 4413/4885CA9 4178/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | CA12 4716/4885CA1 4413/4885CA9 4178/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | CA12 4733/4885CA1 4519/4885CA9 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.